Document Format Files
| Seq | Description | Document | Type | Size |
|---|---|---|---|---|
| 1 | F-4 | tm2226545-14_f4.htm | F-4 | 11065933 |
| 2 | EXHIBIT 3.2 | tm2226545d15_ex3-2.htm | EX-3.2 | 452252 |
| 3 | EXHIBIT 4.5 | tm2226545d15_ex4-5.htm | EX-4.5 | 4000 |
| 4 | EXHIBIT 4.6 | tm2226545d15_ex4-6.htm | EX-4.6 | 25025 |
| 5 | EXHIBIT 5.1 | tm2226545d15_ex5-1.htm | EX-5.1 | 413256 |
| 6 | EXHIBIT 5.2 | tm2226545d15_ex5-2.htm | EX-5.2 | 23417 |
| 7 | EXHIBIT 10.5 | tm2226545d15_ex10-5.htm | EX-10.5 | 153515 |
| 8 | EXHIBIT 10.6 | tm2226545d15_ex10-6.htm | EX-10.6 | 61828 |
| 9 | EXHIBIT 10.9 | tm2226545d15_ex10-9.htm | EX-10.9 | 1391125 |
| 10 | EXHIBIT 10.10 | tm2226545d15_ex10-10.htm | EX-10.10 | 161243 |
| 11 | EXHIBIT 10.11 | tm2226545d15_ex10-11.htm | EX-10.11 | 42212 |
| 12 | EXHIBIT 10.12 | tm2226545d15_ex10-12.htm | EX-10.12 | 148292 |
| 13 | EXHIBIT 10.13 | tm2226545d15_ex10-13.htm | EX-10.13 | 51057 |
| 14 | EXHIBIT 21.1 | tm2226545d15_ex21-1.htm | EX-21.1 | 3576 |
| 15 | EXHIBIT 23.1 | tm2226545d15_ex23-1.htm | EX-23.1 | 3139 |
| 16 | EXHIBIT 23.2 | tm2226545d15_ex23-2.htm | EX-23.2 | 3374 |
| 17 | EXHIBIT 23.3 | tm2226545d15_ex23-3.htm | EX-23.3 | 5983 |
| 18 | EXHIBIT 23.7 | tm2226545d15_ex23-7.htm | EX-23.7 | 2408 |
| 19 | EXHIBIT 99.2 | tm2226545d15_ex99-2.htm | EX-99.2 | 84319 |
| 20 | EXHIBIT 99.3 | tm2226545d15_ex99-3.htm | EX-99.3 | 39906 |
| 21 | EXHIBIT 99.4 | tm2226545d15_ex99-4.htm | EX-99.4 | 3532 |
| 22 | EXHIBIT 99.5 | tm2226545d15_ex99-5.htm | EX-99.5 | 3520 |
| 23 | EX-FILING FEES | tm2226545d15_ex-filingfees.htm | EX-FILING FEES | 25845 |
| 24 | GRAPHIC | ft_valuescope-4c.jpg | GRAPHIC | 22051 |
| 25 | GRAPHIC | lg_summithealthcare-4c.jpg | GRAPHIC | 41162 |
| 26 | GRAPHIC | lg_valuescope-4clr.jpg | GRAPHIC | 25878 |
| 27 | GRAPHIC | lg_weiwei-4c.jpg | GRAPHIC | 42031 |
| 28 | GRAPHIC | lg_ysbiopharma-4c.jpg | GRAPHIC | 30484 |
| 29 | GRAPHIC | lh_report-4c.jpg | GRAPHIC | 49698 |
| 30 | GRAPHIC | tm2226545d1-bc_china4clr.jpg | GRAPHIC | 161620 |
| 31 | GRAPHIC | tm2226545d1-bc_figure24c.jpg | GRAPHIC | 159350 |
| 32 | GRAPHIC | tm2226545d1-bc_global4clr.jpg | GRAPHIC | 133094 |
| 33 | GRAPHIC | tm2226545d1-bc_gvaccine4clr.jpg | GRAPHIC | 161619 |
| 34 | GRAPHIC | tm2226545d1-bc_rabiescarr4c.jpg | GRAPHIC | 35445 |
| 35 | GRAPHIC | tm2226545d1-bc_rabiesmark4c.jpg | GRAPHIC | 73194 |
| 36 | GRAPHIC | tm2226545d1-fc_figure254clr.jpg | GRAPHIC | 40836 |
| 37 | GRAPHIC | tm2226545d1-fc_groupa4clr.jpg | GRAPHIC | 56869 |
| 38 | GRAPHIC | tm2226545d1-fc_organbw.jpg | GRAPHIC | 40722 |
| 39 | GRAPHIC | tm2226545d1-fc_organibw.jpg | GRAPHIC | 70259 |
| 40 | GRAPHIC | tm2226545d1-fc_phase14clr.jpg | GRAPHIC | 68965 |
| 41 | GRAPHIC | tm2226545d1-fc_purchas4c.jpg | GRAPHIC | 72688 |
| 42 | GRAPHIC | tm2226545d1-fc_summarbwlr.jpg | GRAPHIC | 161712 |
| 43 | GRAPHIC | tm2226545d1-fc_trialde4clr.jpg | GRAPHIC | 136720 |
| 44 | GRAPHIC | tm2226545d1-fc_trials4clr.jpg | GRAPHIC | 131050 |
| 45 | GRAPHIC | tm2226545d1-fc_uae4clr.jpg | GRAPHIC | 177313 |
| 46 | GRAPHIC | tm2226545d1-fc_yishe4c.jpg | GRAPHIC | 118275 |
| 47 | GRAPHIC | tm2226545d1-lc_median4clr.jpg | GRAPHIC | 45212 |
| 48 | GRAPHIC | tm2226545d1-tbl_cde4c.jpg | GRAPHIC | 123862 |
| 49 | GRAPHIC | tm2226545d1-tbl_cell4c.jpg | GRAPHIC | 145065 |
| 50 | GRAPHIC | tm2226545d1-tbl_company4c.jpg | GRAPHIC | 142948 |
| 51 | GRAPHIC | tm2226545d1-tbl_drug4c.jpg | GRAPHIC | 113950 |
| 52 | GRAPHIC | tm2226545d1-tbl_hbv4c.jpg | GRAPHIC | 89994 |
| 53 | GRAPHIC | tm2226545d1-tbl_rabies4clr.jpg | GRAPHIC | 27987 |
| 54 | GRAPHIC | tm2226545d1-tbl_study4clr.jpg | GRAPHIC | 155089 |
| 55 | GRAPHIC | tm2226545d1-tbl_vaccine4c.jpg | GRAPHIC | 197167 |
| 56 | GRAPHIC | tm2226545d1-tbl_vacphi4c.jpg | GRAPHIC | 67604 |
| 57 | GRAPHIC | tm2226545d1-tbl_vacsing4c.jpg | GRAPHIC | 106740 |
| 58 | GRAPHIC | tm2226545d1-txt_chinese1bw.jpg | GRAPHIC | 9217 |
| 59 | GRAPHIC | tm2226545d1-txt_chinese2bw.jpg | GRAPHIC | 2106 |
| 60 | GRAPHIC | tm2226545d15_ex10-10img001.jpg | GRAPHIC | 2532 |
| 61 | GRAPHIC | tm2226545d15_ex10-9img001.jpg | GRAPHIC | 3394 |
| 62 | GRAPHIC | tm2226545d15_ex10-9img002.jpg | GRAPHIC | 3169 |
| 63 | GRAPHIC | tm2226545d15_ex10-9img003.jpg | GRAPHIC | 2690 |
| 64 | GRAPHIC | tm2226545d15_ex23-2img002.jpg | GRAPHIC | 10992 |
| 65 | GRAPHIC | tm2226545d15_ex23-2img003.jpg | GRAPHIC | 11444 |
| 66 | GRAPHIC | tm2226545d15_ex3-2sp1img01.jpg | GRAPHIC | 10546 |
| 67 | GRAPHIC | tm2226545d15_ex3-2sp1img02.jpg | GRAPHIC | 10593 |
| 68 | GRAPHIC | tm2226545d15_ex3-2sp2img02.jpg | GRAPHIC | 7845 |
| 69 | GRAPHIC | tm2226545d15_ex3-2sp3img01.jpg | GRAPHIC | 7553 |
| 70 | GRAPHIC | tm2226545d15_ex5-1img01.jpg | GRAPHIC | 3826 |
| 71 | GRAPHIC | tm2226545d15_ex5-1img02.jpg | GRAPHIC | 18699 |
| 72 | GRAPHIC | tm2226545d15_ex5-2img001.jpg | GRAPHIC | 6822 |
| 73 | GRAPHIC | tm2226545d15_ex5-2img002.jpg | GRAPHIC | 3842 |
| 74 | GRAPHIC | tm2226545d15_ex5-2img005.jpg | GRAPHIC | 2924 |
| 75 | GRAPHIC | tm2226545d15_ex5-2img006.jpg | GRAPHIC | 2924 |
| 76 | GRAPHIC | tm2226545d15_ex99-3img001.jpg | GRAPHIC | 22636 |
| 77 | GRAPHIC | tm2226545d1_ex3-2img035.jpg | GRAPHIC | 22564 |
| 78 | GRAPHIC | tm2226545d7-bc_11figure4clr.jpg | GRAPHIC | 110714 |
| 79 | GRAPHIC | tm2226545d7-bc_12figure4c.jpg | GRAPHIC | 70777 |
| 80 | GRAPHIC | tm2226545d7-bc_13figure4c.jpg | GRAPHIC | 65536 |
| 81 | GRAPHIC | tm2226545d7-bc_14figure4c.jpg | GRAPHIC | 56402 |
| 82 | GRAPHIC | tm2226545d7-bc_17figure4clr.jpg | GRAPHIC | 39655 |
| 83 | GRAPHIC | tm2226545d7-bc_18figure4clr.jpg | GRAPHIC | 42219 |
| 84 | GRAPHIC | tm2226545d7-bc_19figure4clr.jpg | GRAPHIC | 45985 |
| 85 | GRAPHIC | tm2226545d7-bc_21figure4clr.jpg | GRAPHIC | 83051 |
| 86 | GRAPHIC | tm2226545d7-bc_23figure4c.jpg | GRAPHIC | 100243 |
| 87 | GRAPHIC | tm2226545d7-bc_24figure4c.jpg | GRAPHIC | 29285 |
| 88 | GRAPHIC | tm2226545d7-bc_3figure4c.jpg | GRAPHIC | 55527 |
| 89 | GRAPHIC | tm2226545d7-bc_4figure4c.jpg | GRAPHIC | 52113 |
| 90 | GRAPHIC | tm2226545d7-bc_5figure4clr.jpg | GRAPHIC | 117154 |
| 91 | GRAPHIC | tm2226545d7-bc_8figure4c.jpg | GRAPHIC | 47052 |
| 92 | GRAPHIC | tm2226545d7-bc_9figure4c.jpg | GRAPHIC | 70600 |
| 93 | GRAPHIC | tm2226545d7-bc_armb4c.jpg | GRAPHIC | 130724 |
| 94 | GRAPHIC | tm2226545d7-bc_figure144clr.jpg | GRAPHIC | 55580 |
| 95 | GRAPHIC | tm2226545d7-bc_figure84clr.jpg | GRAPHIC | 157644 |
| 96 | GRAPHIC | tm2226545d7-fc_combniatbw.jpg | GRAPHIC | 55353 |
| 97 | GRAPHIC | tm2226545d7-fc_corporatebw.jpg | GRAPHIC | 76412 |
| 98 | GRAPHIC | tm2226545d7-lc_10figure4clr.jpg | GRAPHIC | 96436 |
| 99 | GRAPHIC | tm2226545d7-lc_25figure4c.jpg | GRAPHIC | 71291 |
| 100 | GRAPHIC | tm2226545d7-lc_7figure4c.jpg | GRAPHIC | 77068 |
| 101 | GRAPHIC | tm2226545d7-lc_figure24c.jpg | GRAPHIC | 62099 |
| 102 | GRAPHIC | tm2226545d7-ph_figure14clr.jpg | GRAPHIC | 139033 |
| 103 | GRAPHIC | tm2226545d7-ph_figure64clr.jpg | GRAPHIC | 205584 |
| 104 | GRAPHIC | tm2226545d7-tbl_pipelin4c.jpg | GRAPHIC | 233690 |
| 105 | GRAPHIC | tm2226545d15_ex23-2img0002.jpg | GRAPHIC | 33551 |
| 106 | GRAPHIC | tm2226545d15_ex23-2img0001.jpg | GRAPHIC | 51848 |
| Complete submission text file | 0001104659-22-130315.txt | 22156601 |
IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0331
Type: F-4 | Act: 33 | File No.: 333-269031 | Film No.: 221491622
SIC: 2834 Pharmaceutical Preparations
